Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
暂无分享,去创建一个
T. Brümmendorf | M. Baccarani | H. Kantarjian | J. Cortes | H. Khoury | A. Countouriotis | E. Leip | C. Gambacorti-Passerini | Dong-Wook Kim | A. Zaritskey | N. Besson | V. Kelly | H. Khoury | T. Brümmendorf | Jorge E. Cortés | Dong-Wook Kim